<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US">
	<id>https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3AShareholder_rights_plan_%28poison_pill%29</id>
	<title>Definition:Shareholder rights plan (poison pill) - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3AShareholder_rights_plan_%28poison_pill%29"/>
	<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Shareholder_rights_plan_(poison_pill)&amp;action=history"/>
	<updated>2026-05-02T18:22:20Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://www.insurerbrain.com/w/index.php?title=Definition:Shareholder_rights_plan_(poison_pill)&amp;diff=20321&amp;oldid=prev</id>
		<title>PlumBot: Bot: Creating new article from JSON</title>
		<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Shareholder_rights_plan_(poison_pill)&amp;diff=20321&amp;oldid=prev"/>
		<updated>2026-03-17T15:52:27Z</updated>

		<summary type="html">&lt;p&gt;Bot: Creating new article from JSON&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;🛡️ &amp;#039;&amp;#039;&amp;#039;Shareholder rights plan (poison pill)&amp;#039;&amp;#039;&amp;#039; is a defensive mechanism adopted by the board of a publicly traded insurance company to deter hostile takeover attempts by making the acquisition prohibitively expensive for an unwelcome bidder. The plan typically grants existing shareholders the right to purchase additional shares at a steep discount if any single investor — or group acting in concert — crosses a specified ownership threshold, usually between 10 and 20 percent. While the device originated in U.S. corporate law during the 1980s, its principles have influenced takeover defense thinking globally, including in markets where insurers are frequent acquisition targets.&lt;br /&gt;
&lt;br /&gt;
⚙️ The mechanics activate automatically once a triggering event occurs. When an acquirer&amp;#039;s stake breaches the threshold, all other shareholders receive rights to buy newly issued shares at half their market price, massively diluting the hostile bidder&amp;#039;s position and escalating the cost of gaining control. Insurance companies have adopted poison pills for reasons specific to the sector: a hostile acquirer might undervalue long-tail [[Definition:Loss reserves | reserves]], underestimate the franchise value of [[Definition:Distribution channel | distribution]] relationships, or plan to extract short-term gains by weakening [[Definition:Solvency | solvency]] margins. Regulatory considerations add another layer — most jurisdictions require that any change of control of a licensed insurer receive prior approval from the relevant [[Definition:Insurance regulator | insurance regulator]], a process that can be lengthy and uncertain. A poison pill gives the target&amp;#039;s board additional negotiating time while that regulatory review unfolds.&lt;br /&gt;
&lt;br /&gt;
⚖️ Despite their protective intent, shareholder rights plans remain controversial within insurance markets. Critics argue they entrench underperforming management teams and prevent shareholders from realizing a premium that a change-of-control transaction would deliver. Proxy advisory firms and institutional investors frequently recommend voting against their renewal. Proponents counter that insurers, given their policyholder obligations and complex balance sheets, require more deliberate evaluation than companies in other sectors — a rushed takeover could jeopardize [[Definition:Policyholder | policyholder]] protection and trigger [[Definition:Rating agency | rating agency]] downgrades. In practice, many insurance-sector poison pills serve as a bargaining tool rather than an absolute barrier, compelling bidders to negotiate directly with the board rather than appeal straight to shareholders through a tender offer.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Related concepts:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
{{Div col|colwidth=20em}}&lt;br /&gt;
* [[Definition:Mergers and acquisitions (M&amp;amp;A)]]&lt;br /&gt;
* [[Definition:Change of control]]&lt;br /&gt;
* [[Definition:Corporate governance]]&lt;br /&gt;
* [[Definition:Shareholder vote]]&lt;br /&gt;
* [[Definition:Takeover defense]]&lt;br /&gt;
* [[Definition:Regulatory approval]]&lt;br /&gt;
{{Div col end}}&lt;/div&gt;</summary>
		<author><name>PlumBot</name></author>
	</entry>
</feed>